PATENT CLAIM ANALYSIS

Application Number: 16038734
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "332000"]

Abstract:
The invention relates to oligopyridylamide alpha-helix mimetic compounds and their use to inhibit p53 aggregation and restore its tumor suppressor function for treating diseases, e.g., cancers, associated with p53 mutations, e.g., R248W p53 mutation.

Claim (Index 5):
The method of  claim 4 , wherein the cell is in a subject.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.29032
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14521972', '14409607', '13721491', '12344868', '14412185']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7606313179829227
- 35 USC 102 Novelty (BERT): 0.5261584030648486
- Combined Prediction Score: 0.7371840264911154
- Mean Citation Score: 278.346004
- Max Citation Score: 285.72833
- Similarity Product: 175.2774697542524

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test